Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 124

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 124
---
(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. * * * *

| Cytokinetics, Inc.|2025 Proxy Statement |     | A-13 |

TABLE OF CONTENTS APPENDIX B CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOKINETICS, INCORPORATED CYTOKINETICS, INCORPORATED , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “ DGCL ”), hereby certifies that: FIRST: The name of the corporation isCYTOKINETICS, INCORPORATED . SECOND: The date on which the Certificate of Incorporation of the corporation was originally filed with the Secretary of State of the State of Delaware was August 5, 1997. THIRD: The Board of Directors of the corporation, acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions to amend the Amended and Restated Certificate of Incorporation of the corporation to increase the number of authorized shares of Common Stock to 326,000,000. Specifically, the first sentence of Article IV is hereby amended by deleting “163,000,000 shares of Common Stock” and replacing the same with “326,000,000 shares of Common Stock.” FOURTH: This Certificate of Amendment was duly adopted by the stockholders of the corporation in accordance with the provisions of Section 242 of the DGCL. [Signature Page Follows]

| Cytokinetics, Inc.|2025 Proxy Statement |     | B-1 |

TABLE OF CONTENTS APPENDIX B

IN WITNESS WHEREOF , the corporation has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer this [•] day of [•], 2025.

| CYTOKINETICS, INCORPORATED |     |                                       |
| By:                        |     |                                       |
|                            |     | ROBERT I. BLUM                        
 President and Chief Executive Officer |

| B-2 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS TABLE OF CONTENTS